Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Capricor Therapeutics (CAPR) EBT (2016 - 2025)

Capricor Therapeutics has reported EBT over the past 15 years, most recently at -$27.1 million for Q4 2025.

  • Quarterly results put EBT at -$27.1 million for Q4 2025, down 287.11% from a year ago — trailing twelve months through Dec 2025 was -$101.9 million (down 152.44% YoY), and the annual figure for FY2025 was -$105.0 million, down 159.58%.
  • EBT for Q4 2025 was -$27.1 million at Capricor Therapeutics, down from -$24.6 million in the prior quarter.
  • Over the last five years, EBT for CAPR hit a ceiling of -$829093.0 in Q4 2023 and a floor of -$27.1 million in Q4 2025.
  • Median EBT over the past 5 years was -$7.5 million (2022), compared with a mean of -$10.7 million.
  • Biggest five-year swings in EBT: soared 89.21% in 2023 and later plummeted 745.46% in 2024.
  • Capricor Therapeutics' EBT stood at -$6.4 million in 2021, then decreased by 20.79% to -$7.7 million in 2022, then soared by 89.21% to -$829093.0 in 2023, then plummeted by 745.46% to -$7.0 million in 2024, then tumbled by 287.11% to -$27.1 million in 2025.
  • The last three reported values for EBT were -$27.1 million (Q4 2025), -$24.6 million (Q3 2025), and -$25.9 million (Q2 2025) per Business Quant data.